PL3153514T3 - Chinazolinony jako inhibitory ludzkiej 3-kinazy fosfatydyloinozytolowej delta - Google Patents

Chinazolinony jako inhibitory ludzkiej 3-kinazy fosfatydyloinozytolowej delta

Info

Publication number
PL3153514T3
PL3153514T3 PL16185213T PL16185213T PL3153514T3 PL 3153514 T3 PL3153514 T3 PL 3153514T3 PL 16185213 T PL16185213 T PL 16185213T PL 16185213 T PL16185213 T PL 16185213T PL 3153514 T3 PL3153514 T3 PL 3153514T3
Authority
PL
Poland
Prior art keywords
quinazolinones
inhibitors
kinase delta
human phosphatidylinositol
phosphatidylinositol
Prior art date
Application number
PL16185213T
Other languages
English (en)
Polish (pl)
Inventor
Kerry W. Fowler
Danwen Huang
Edward A. Kesicki
Hua Chee Ooi
Amy R. Oliver
Fuqiang Ruan
Jennifer Treiberg
Kamal Deep Puri
Original Assignee
Icos Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34969603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3153514(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icos Corporation filed Critical Icos Corporation
Publication of PL3153514T3 publication Critical patent/PL3153514T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
PL16185213T 2004-05-13 2005-05-12 Chinazolinony jako inhibitory ludzkiej 3-kinazy fosfatydyloinozytolowej delta PL3153514T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57078404P 2004-05-13 2004-05-13
EP16185213.2A EP3153514B1 (en) 2004-05-13 2005-05-12 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
EP05752122.1A EP1761540B1 (en) 2004-05-13 2005-05-12 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
PCT/US2005/016778 WO2005113556A1 (en) 2004-05-13 2005-05-12 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta

Publications (1)

Publication Number Publication Date
PL3153514T3 true PL3153514T3 (pl) 2022-01-10

Family

ID=34969603

Family Applications (3)

Application Number Title Priority Date Filing Date
PL16185213T PL3153514T3 (pl) 2004-05-13 2005-05-12 Chinazolinony jako inhibitory ludzkiej 3-kinazy fosfatydyloinozytolowej delta
PL13150110T PL2612862T3 (pl) 2004-05-13 2005-05-12 Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
PL05752122T PL1761540T3 (pl) 2004-05-13 2005-05-12 Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL13150110T PL2612862T3 (pl) 2004-05-13 2005-05-12 Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
PL05752122T PL1761540T3 (pl) 2004-05-13 2005-05-12 Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta

Country Status (23)

Country Link
US (14) US7932260B2 (cg-RX-API-DMAC7.html)
EP (4) EP3943494A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007537291A (cg-RX-API-DMAC7.html)
CN (2) CN102229609A (cg-RX-API-DMAC7.html)
AU (2) AU2005245875C1 (cg-RX-API-DMAC7.html)
BE (1) BE2017C002I2 (cg-RX-API-DMAC7.html)
CA (1) CA2566609C (cg-RX-API-DMAC7.html)
CY (3) CY2016046I1 (cg-RX-API-DMAC7.html)
DK (2) DK1761540T3 (cg-RX-API-DMAC7.html)
ES (3) ES2605792T3 (cg-RX-API-DMAC7.html)
FR (1) FR17C1007I2 (cg-RX-API-DMAC7.html)
HR (2) HRP20161751T1 (cg-RX-API-DMAC7.html)
HU (3) HUE030950T2 (cg-RX-API-DMAC7.html)
IL (4) IL179176A (cg-RX-API-DMAC7.html)
LT (3) LT1761540T (cg-RX-API-DMAC7.html)
LU (1) LUC00005I2 (cg-RX-API-DMAC7.html)
ME (2) ME02688B (cg-RX-API-DMAC7.html)
NL (1) NL300867I2 (cg-RX-API-DMAC7.html)
PL (3) PL3153514T3 (cg-RX-API-DMAC7.html)
PT (3) PT2612862T (cg-RX-API-DMAC7.html)
RS (2) RS55546B1 (cg-RX-API-DMAC7.html)
SI (2) SI2612862T1 (cg-RX-API-DMAC7.html)
WO (2) WO2005113554A2 (cg-RX-API-DMAC7.html)

Families Citing this family (416)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
CA2566436C (en) * 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
CN102229609A (zh) * 2004-05-13 2011-11-02 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
CA2598409A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB2431156A (en) * 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
US20080032960A1 (en) * 2006-04-04 2008-02-07 Regents Of The University Of California PI3 kinase antagonists
NZ576997A (en) * 2006-11-13 2012-02-24 Icos Corp Thienopyrimidinones for treatment of inflammatory disorders and cancers
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
US20110123486A1 (en) * 2007-06-25 2011-05-26 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
FR2918668B1 (fr) * 2007-07-09 2009-08-21 Arkema France Procede ameliore de preparation d'alcoxyamines issues de nitroxydes beta-phosphores.
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
KR20100119745A (ko) * 2007-11-13 2010-11-10 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
RU2537549C2 (ru) * 2008-01-04 2015-01-10 Интелликайн ЭлЭлСи Некоторые химические структуры, композиции и способы
AU2014203687B2 (en) * 2008-01-04 2016-04-14 Intellikine Llc Certain chemical entities, compositions and methods
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009128520A1 (ja) * 2008-04-18 2009-10-22 塩野義製薬株式会社 Ｐ１３ｋ阻害活性を有する複素環化合物
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
PL2323992T3 (pl) * 2008-07-29 2017-01-31 Boehringer Ingelheim International Gmbh 5-alkinylo-pirymidyny
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20170060179A (ko) * 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
CN102317282A (zh) 2009-02-12 2012-01-11 安斯泰来制药有限公司 杂环衍生物
PE20120602A1 (es) 2009-03-24 2012-05-21 Gilead Calistoga Llc ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
MX2011011036A (es) * 2009-04-20 2012-01-20 Gilead Calistoga Llc Metodos de tratamiento para tumores solidos.
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
TW201602113A (zh) 2009-06-29 2016-01-16 英塞特公司 作為ｐｉ３ｋ抑制劑之嘧啶酮
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
CA2773848A1 (en) * 2009-09-09 2011-03-17 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
GB0918249D0 (en) * 2009-10-19 2009-12-02 Respivert Ltd Compounds
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
BR112012019635A2 (pt) 2010-02-22 2016-05-03 Hoffmann La Roche compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
MX2013000389A (es) 2010-07-14 2013-03-08 Hoffmann La Roche Compuestos de purina selectivos para fosfatidilinositol 3-cinasa p110 delta, y metodods de uso.
BR112013003181B8 (pt) 2010-08-10 2024-02-06 Astellas Pharma Inc Composto heterocíclico, sua composição farmacêutica e seus uso
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
JP2013545749A (ja) * 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
EP2663309B1 (en) 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN106619647A (zh) 2011-02-23 2017-05-10 因特利凯有限责任公司 激酶抑制剂的组合及其用途
US20140213630A1 (en) 2011-03-08 2014-07-31 Thomas Diacovo Methods and pharmaceutical compositions for treating lymphoid malignancy
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
CN102719517B (zh) * 2011-03-29 2015-08-19 中国科学院上海药物研究所 一种检测化合物对人Ⅰ型PI3Ks抑制活性的方法
MX365160B (es) 2011-05-04 2019-05-24 Rhizen Pharmaceuticals Sa Compuestos novedosos como moduladores de proteína cinasas.
CN102838600A (zh) * 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
CN102838601A (zh) * 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 选择性磷酰肌醇3-激酶δ抑制剂
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
SG10201912484RA (en) 2011-09-02 2020-02-27 Incyte Corp Heterocyclylamines as pi3k inhibitors
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
KR102057058B1 (ko) 2011-10-03 2019-12-18 레스피버트 리미티드 P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아
WO2013082540A1 (en) * 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
EA029473B1 (ru) 2011-12-15 2018-03-30 Новартис Аг Применение ингибиторов pi3k для лечения острой и церебральной малярии
AU2015252058A1 (en) * 2012-03-05 2015-11-19 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
UY34656A (es) * 2012-03-05 2013-10-31 Gilead Calistoga Llc Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación
SG11201404522VA (en) 2012-03-13 2014-10-30 Respivert Ltd Crystalline pi3 kinase inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014015523A1 (en) * 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
SG11201501173SA (en) * 2012-08-08 2015-05-28 Kbp Biosciences Co Ltd PI3Kδ INHIBITOR
JP2015529195A (ja) * 2012-08-14 2015-10-05 ギリアード カリストガ エルエルシー 癌を処置するための組合せ治療
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
JP2015533181A (ja) * 2012-10-16 2015-11-19 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． Ｐｉ３ｋ阻害剤としてのピロロトリアジノン誘導体
MX375194B (es) 2012-11-01 2025-03-06 Infinity Pharmaceuticals Inc Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
EP2916868B1 (en) 2012-11-08 2022-05-11 Rhizen Pharmaceuticals S.A. Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
CN104918940B (zh) * 2012-11-16 2017-03-08 默沙东公司 人磷脂酰肌醇3‑激酶δ的嘌呤抑制剂
US9018221B2 (en) 2012-12-21 2015-04-28 Gilead Calistoga, Llc Phosphatidylinositol 3-kinase inhibitors
JP6207100B2 (ja) 2012-12-21 2017-10-04 ギリアード カリストガ エルエルシー イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
CA2898610C (en) * 2013-01-21 2021-01-19 Osaka University Phenoxyalkylamine compound
WO2014128612A1 (en) * 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
TW201522341A (zh) * 2013-03-15 2015-06-16 Respivert Ltd 化合物
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
DK3003309T3 (da) 2013-05-30 2020-12-14 Infinity Pharmaceuticals Inc Behandling af cancer med PI3-kinase-isoform modulatorer
BR112015031475A2 (pt) 2013-06-14 2017-07-25 Gilead Sciences Inc composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
UY35675A (es) * 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015014315A1 (zh) 2013-08-01 2015-02-05 杭州普晒医药科技有限公司 一种抑制剂的晶型及其制备方法和用途
CN104418858B (zh) 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
KR20160058889A (ko) 2013-09-22 2016-05-25 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6584391B2 (ja) 2013-10-10 2019-10-02 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015092810A2 (en) 2013-11-20 2015-06-25 Cadila Healthcare Limited Amorphous form of idelalisib
CA2931615A1 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
AU2014358868A1 (en) 2013-12-05 2016-06-09 Acerta Pharma B.V. Therapeutic combination of a PI3K inhibitor and a BTK inhibitor
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
SG11201604825VA (en) 2013-12-20 2016-07-28 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US9938245B2 (en) 2014-01-15 2018-04-10 The Trustees Of Columbia University In The City Of New York Carbonyl erastin analogs and their use
JP2017503001A (ja) 2014-01-20 2017-01-26 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための療法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN104817559B (zh) * 2014-01-30 2021-05-25 苏州泽璟生物制药股份有限公司 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN106661039B (zh) 2014-02-28 2019-09-13 林伯士拉克许米公司 酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
PT3119397T (pt) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
TW202134236A (zh) 2014-06-12 2021-09-16 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
AU2015274635B2 (en) 2014-06-13 2018-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
MA40059A (fr) * 2014-06-13 2015-12-17 Gilead Sciences Inc Inhibiteurs de la phosphatidylinositol 3-kinase
BR112016028876A2 (pt) 2014-06-13 2017-08-22 Gilead Sciences Inc composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
SG11201609540TA (en) * 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
SG11201610517PA (en) 2014-06-19 2017-01-27 Ariad Pharma Inc Heteroaryl compounds for kinase inhibition
EP3164400A1 (en) 2014-07-04 2017-05-10 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
CN104130261B (zh) * 2014-08-04 2016-03-02 山东康美乐医药科技有限公司 艾德利布的合成方法
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
ES2900184T3 (es) 2014-08-11 2022-03-16 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
CN104262344B (zh) * 2014-08-22 2015-11-04 苏州明锐医药科技有限公司 艾德拉尼的制备方法
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
CN105503877A (zh) 2014-09-24 2016-04-20 和记黄埔医药（上海）有限公司 咪唑并哒嗪类化合物及其用途
ES2881195T3 (es) 2014-09-26 2021-11-29 Gilead Sciences Inc Derivados de aminotriazina útiles como compuestos inhibidores de quinasas que se unen a TANK
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
ES2807785T3 (es) 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
HUE054526T2 (hu) 2014-10-29 2021-09-28 Bicyclerd Ltd MT1-MMP-ra specifikus biciklusos peptid ligandumok
EP3224248B1 (en) 2014-11-01 2021-05-05 Shanghai Fochon Pharmaceutical Co. Ltd Certain protein kinase inhibitors
ES2685252T3 (es) 2014-12-09 2018-10-08 Ratiopharm Gmbh Sal de idelalisib
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
EP3048104A1 (en) 2015-01-20 2016-07-27 Sandoz AG Amorphous and crystalline forms of idelalisib and process for forming the same
WO2016097314A1 (en) * 2014-12-19 2016-06-23 Sandoz Ag Amorphous and crystalline forms of idelalisib and process for forming the same
WO2016108206A2 (en) * 2014-12-31 2016-07-07 Dr. Reddy’S Laboratories Limited Processes for preparation of idelalisib and intermediates thereof
KR101710461B1 (ko) * 2015-01-16 2017-02-27 순천향대학교 산학협력단 키랄 2-플루오로-4-나이트로 부탄산 유도체의 제조방법
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
TWI788655B (zh) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
EP4183789A1 (en) 2015-02-27 2023-05-24 Incyte Holdings Corporation Salts of pi3k inhibitor and processes for their preparation
MY199988A (en) 2015-03-04 2023-12-02 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
US20180064714A1 (en) * 2015-03-13 2018-03-08 Mylan Laboratories Ltd Process for the Preparation of Amorphous Idelalisib and its Premix
WO2016156240A1 (en) * 2015-03-31 2016-10-06 Synthon B.V. Improved process for preparing idelalisib
WO2016157136A1 (en) 2015-04-02 2016-10-06 Mylan Laboratories Ltd Crystalline forms of idelalisib
CN106146502B (zh) * 2015-04-09 2019-01-04 上海医药工业研究院 艾代拉里斯的合成方法及制备中间体
CN104892612B (zh) * 2015-04-15 2017-12-19 上海方楠生物科技有限公司 一种艾德力布的无定型物及其制备方法
CN106146411A (zh) * 2015-04-16 2016-11-23 上海医药工业研究院 (s)-2-(1-氨基-丙基)-5-氟-3-苯基-3h-喹唑啉-4-酮的制备方法
CN106146352A (zh) * 2015-04-16 2016-11-23 上海医药工业研究院 Idelalisib中间体及其制备方法
CN106146503A (zh) * 2015-04-16 2016-11-23 上海医药工业研究院 一种Idelalisib的制备方法
GB201506786D0 (en) * 2015-04-21 2015-06-03 Ucb Biopharma Sprl Therapeutic use
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
CZ2015347A3 (cs) 2015-05-22 2016-11-30 Zentiva, K.S. Pevné formy 5-fluor-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]chinazolin-4-onu a jejich příprava
CN106279171A (zh) * 2015-06-09 2017-01-04 南京安源生物医药科技有限公司 一种Idelalisib的制备方法
WO2016209961A1 (en) 2015-06-23 2016-12-29 Gilead Sciences, Inc. Combination therapies for treating b-cell malignancies
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN107873032B (zh) 2015-07-02 2020-07-17 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
HUE055469T2 (hu) 2015-07-29 2021-11-29 Novartis Ag A LAG-3 elleni antitest molekulákat tartalmazó kombinált terápiák
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
CN115054697B (zh) 2015-08-21 2024-06-11 莫佛塞斯公司 抗-cd19抗体和磷酸肌醇3-激酶抑制剂的组合及其用途
CZ2015575A3 (cs) * 2015-08-26 2017-03-08 Zentiva, K.S. Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava
WO2017040757A1 (en) 2015-09-02 2017-03-09 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CA2997106C (en) 2015-09-08 2024-06-04 Monash University Lymph directing prodrugs
WO2017044720A1 (en) 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
KR102787845B1 (ko) 2015-09-14 2025-03-31 트웰브 테라퓨틱스, 아이엔씨. 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
JP2018530550A (ja) 2015-10-01 2018-10-18 ギリアド サイエンシズ， インコーポレイテッド 癌を治療するためのｂｔｋ阻害剤とチェックポイント阻害剤との組合せ
CN121102186A (zh) 2015-10-23 2025-12-12 纳维托制药有限公司 Sestrin-gator2相互作用的调节剂和其用途
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
TWI730013B (zh) 2015-11-20 2021-06-11 生華生物科技股份有限公司 用於治療癌症的四環喹諾酮類似物組合療法
HU231016B1 (hu) * 2015-11-30 2019-11-28 Egis Gyógyszergyár Zrt. Idelalisib új polimorf és szolvát formája
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CU20180059A7 (es) 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
WO2017130221A1 (en) * 2016-01-29 2017-08-03 Sun Pharmaceutical Industries Limited Improved process for the preparation of idelalisib
EP3411376A1 (en) 2016-02-03 2018-12-12 Lupin Limited A process for the preparation of phosphatidylinositol 3-kinase inhibitor
CN107033145B (zh) * 2016-02-04 2019-11-22 浙江大学 苯并噻嗪和苯并噻二嗪类化合物及制备和应用
EP3423057A1 (en) 2016-03-04 2019-01-09 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
PT3426243T (pt) 2016-03-09 2021-08-19 Raze Therapeutics Inc Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
US11014882B2 (en) * 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
AU2017248354A1 (en) 2016-04-08 2018-10-04 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106074430A (zh) * 2016-06-13 2016-11-09 佛山市腾瑞医药科技有限公司 一种艾代拉利司泡腾片及其制备方法
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
WO2017223239A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017221272A1 (en) * 2016-06-23 2017-12-28 Sun Pharmaceutical Industries Limited Process for the preparation of idelalisib
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
KR101932146B1 (ko) * 2016-07-14 2018-12-24 주식회사 바이오웨이 Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물
EP3272348A1 (en) 2016-07-21 2018-01-24 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising idelalisib
MA45848A (fr) 2016-08-04 2019-06-12 Gilead Sciences Inc Cobicistat destiné à être utilisé dans des traitements du cancer
MA46093A (fr) 2016-09-02 2021-05-19 Gilead Sciences Inc Composés modulateurs du recepteur de type toll
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN109952303B (zh) 2016-10-14 2022-10-21 林伯士拉克许米公司 Tyk2抑制剂及其用途
CN106632337B (zh) * 2016-10-18 2018-11-20 湖北生物医药产业技术研究院有限公司 艾代拉里斯的晶型、药物组合物、制备方法和用途
US10647713B2 (en) 2016-10-21 2020-05-12 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
US20180133212A1 (en) 2016-11-03 2018-05-17 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
EP3538091A4 (en) 2016-11-08 2020-06-10 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
WO2018097977A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
EP3565638B8 (en) 2017-01-06 2024-04-10 BicycleRD Limited Bicycle conjugate for treating cancer
WO2018137598A1 (en) 2017-01-24 2018-08-02 I-Mab Anti-cd73 antibodies and uses thereof
TWI754011B (zh) 2017-02-24 2022-02-01 美商基利科學股份有限公司 布魯頓氏酪胺酸激酶之抑制劑
EP3585789A1 (en) 2017-02-24 2020-01-01 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
WO2018165240A1 (en) 2017-03-08 2018-09-13 Nimbus Lakshmi, Inc. Tyk2 inhibitors, uses, and methods for production thereof
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
US10870650B2 (en) 2017-04-24 2020-12-22 Natco Pharma Limited Process for the preparation of amorphous idelalisib
EP3615019B1 (en) 2017-04-26 2025-06-04 Navitor Pharmaceuticals, Inc. Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
CN109111447A (zh) 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
US10899798B2 (en) 2017-06-26 2021-01-26 Bicyclerd Limited Bicyclic peptide ligands with detectable moieties and uses thereof
EP3658557B1 (en) 2017-07-28 2024-06-05 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
WO2019028055A1 (en) * 2017-07-31 2019-02-07 The Trustees Of Columbia Univeristy In The City Of New York COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AC T-LYMPHOBLASTIC LYMPHOBLASTIC LEUKEMIA
US11261214B2 (en) 2017-08-04 2022-03-01 Bicycletx Limited Bicyclic peptide ligand specific for CD137
EP3668550A1 (en) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
US20200291096A1 (en) 2017-08-14 2020-09-17 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
EP3675838A4 (en) 2017-08-29 2021-04-21 PureTech LYT, Inc. LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
IL272909B2 (en) 2017-09-07 2024-01-01 Univ Res Inst Inc Augusta Specific akt3 activator and uses thereof
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
WO2019092253A1 (en) * 2017-11-10 2019-05-16 Synthon B.V. Process for preparing idelalisib
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
WO2019126378A1 (en) 2017-12-19 2019-06-27 Ariya Therapeutics, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
EP3728282B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11701361B2 (en) * 2018-01-05 2023-07-18 National Institutes Of Health (Nch), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3740468B1 (en) 2018-01-20 2025-12-31 Sunshine Lake Pharma Co., Ltd. Substituted Aminopyrimidine Compounds and Methods of Use
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR20200115620A (ko) 2018-01-29 2020-10-07 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
MX2020007799A (es) 2018-01-29 2020-09-18 Merck Patent Gmbh Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
CN108409674A (zh) * 2018-02-09 2018-08-17 南京法恩化学有限公司 一种艾代拉利司中间体的制备方法
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
WO2019168688A2 (en) 2018-02-15 2019-09-06 Senhwa Biosciences, Inc. Quinolone analogs and their salts, compositions, and method for their use
US10875894B2 (en) 2018-02-23 2020-12-29 Bicycletx Limited Multimeric bicyclic peptide ligands
AU2019229258B2 (en) 2018-02-27 2023-09-14 Artax Biopharma Inc. Chromene derivatives as inhibitors of TCR-Nck interaction
CN108409740B (zh) * 2018-03-14 2020-05-08 盐城师范学院 一种艾代拉里斯制备方法
WO2019178596A1 (en) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
ES2919572T3 (es) 2018-04-24 2022-07-27 Merck Patent Gmbh Compuestos antiproliferación y usos de los mismos
ES2969982T3 (es) 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
WO2019217780A1 (en) 2018-05-11 2019-11-14 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
CA3099152C (en) 2018-05-14 2023-10-24 Gilead Sciences, Inc. Mcl-1 inhibitors
EP3802609A2 (en) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Psma binding agents and uses thereof
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CN119258070A (zh) 2018-06-01 2025-01-07 因赛特公司 治疗pi3k相关病症的给药方案
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
EA202092692A1 (ru) 2018-06-15 2021-04-21 Навитор Фармасьютикалз, Инк. Аналоги рапамицина и их применения
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
TWI809427B (zh) 2018-07-13 2023-07-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US20200077906A1 (en) 2018-09-07 2020-03-12 Augusta University Research Institute, Inc. Method and System for Monitoring Brain Function and Intracranial Pressure
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
AU2019360941B2 (en) 2018-10-15 2025-02-27 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
US10919937B2 (en) 2018-10-23 2021-02-16 Bicycletx Limited Bicyclic peptide ligands and uses thereof
MX2021004710A (es) 2018-10-24 2021-06-04 Navitor Pharm Inc Compuestos polimorficos y usos de los mismos.
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
ES2979163T3 (es) 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
JP7530360B2 (ja) 2018-11-30 2024-08-07 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
CN109593066B (zh) * 2018-12-21 2020-06-19 上海交通大学 一种用于治疗肠道细菌感染的叶酸拮抗剂及其制备与应用
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
CA3126034A1 (en) 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
MA55717A (fr) 2019-04-19 2022-02-23 Janssen Biotech Inc Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
SG11202113154YA (en) 2019-05-31 2021-12-30 Ikena Oncology Inc Tead inhibitors and uses thereof
US20220305115A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
KR102776925B1 (ko) 2019-06-25 2025-03-11 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
JP7454645B2 (ja) 2019-07-16 2024-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン並びにその作製方法及び使用方法
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
AU2020345962A1 (en) 2019-09-11 2022-03-31 Vincere Biosciences, Inc. USP30 inhibitors and uses thereof
BR112022004451A2 (pt) 2019-09-13 2022-06-21 Nimbus Saturn Inc Antagonistas de hpk1 e usos dos mesmos
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
IL315295A (en) 2019-09-30 2024-10-01 Gilead Sciences Inc Hbv vaccines and methods treating hbv
CA3153501A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
US11723890B2 (en) 2019-11-01 2023-08-15 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN115209897A (zh) 2019-12-05 2022-10-18 安纳库利亚治疗公司 雷帕霉素类似物及其用途
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
KR20220151160A (ko) 2019-12-23 2022-11-14 카이메라 쎄라퓨틱스 인코포레이티드 Smarca 분해제 및 이의 용도
PH12022551441A1 (en) 2019-12-24 2023-11-20 Carna Biosciences Inc Diacylglycerol kinase modulating compounds
KR20210095495A (ko) * 2020-01-23 2021-08-02 주식회사 바이오웨이 신규한 퀴나졸리논 화합물 및 이를 포함하는 약학적 조성물
US20210268115A1 (en) 2020-02-05 2021-09-02 Puretech Lyt, Inc. Lipid prodrugs of neurosteroids
CR20220396A (es) 2020-02-14 2022-11-14 Jounce Therapeutics Inc Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2021188948A1 (en) 2020-03-19 2021-09-23 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
CN113512042B (zh) * 2020-04-09 2024-06-11 成都赜灵生物医药科技有限公司 取代喹唑啉-4-酮类化合物及其制备方法和用途
US20240043427A1 (en) 2020-05-01 2024-02-08 Gilead Sciences, Inc. Cd73 compounds
CA3178569A1 (en) * 2020-05-16 2021-11-25 Zuwen ZHOU Compounds as protein kinase inhibitors
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
JP2023538906A (ja) 2020-08-17 2023-09-12 バイシクルティーエクス・リミテッド ネクチン－４に特異的な二環コンジュゲート及びその使用
CN111840297B (zh) * 2020-08-24 2023-06-16 天津济坤医药科技有限公司 艾代拉里斯在制备用于治疗肝纤维化疾病的药物中的应用
US12331046B2 (en) 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4255895A1 (en) 2020-12-02 2023-10-11 Ikena Oncology, Inc. Tead inhibitors and uses thereof
JP2024503300A (ja) 2020-12-30 2024-01-25 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
JP2024504758A (ja) 2021-01-28 2024-02-01 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ結合タンパク質及びその使用
EP4288430A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
US20230113202A1 (en) 2021-02-02 2023-04-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
JP2024506909A (ja) 2021-02-12 2024-02-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
US11773103B2 (en) 2021-02-15 2023-10-03 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
AU2022220043A1 (en) 2021-02-15 2023-08-31 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
EP4301756A4 (en) 2021-03-05 2025-02-26 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND THEIR USES
JP2024513011A (ja) 2021-03-29 2024-03-21 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
WO2022217276A1 (en) 2021-04-09 2022-10-13 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
JP2024514879A (ja) 2021-04-16 2024-04-03 イケナ オンコロジー， インコーポレイテッド Ｍｅｋ阻害剤及びその使用
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4392421A1 (en) 2021-08-25 2024-07-03 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CA3236265A1 (en) 2021-10-29 2023-05-04 William Leong Irak4 degraders and synthesis thereof
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
ES2999273T3 (en) 2022-03-17 2025-02-25 Gilead Sciences Inc Ikaros zinc finger family degraders and uses thereof
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CN119487038A (zh) 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
CN117088867A (zh) * 2022-05-19 2023-11-21 杭州百诚医药科技股份有限公司 可吸入型芳环并噻嗪及类似物、含其的药物组合物及其在抗炎、抗肿瘤中的应用
CA3252253A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
IL318575A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
TW202416972A (zh) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 經取代之吡啶酮gpr84拮抗劑及其用途
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
AR131141A1 (es) 2022-11-22 2025-02-19 Pic Therapeutics Inc Inhibidores de eif4e y usos de los mismos
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
IL321486A (en) 2023-06-23 2025-08-01 Kymera Therapeutics Inc Iraqi joints and their uses
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025062372A1 (en) 2023-09-21 2025-03-27 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35862A (en) * 1862-07-08 Improved portable evaporator for saccharine jutces
DE1249281B (cg-RX-API-DMAC7.html) 1963-05-18
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
DE2027645A1 (de) 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
US3897432A (en) 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
NL7204972A (cg-RX-API-DMAC7.html) 1971-04-21 1972-10-24
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2644265C2 (de) 1976-09-30 1983-02-10 Bayer Ag, 5090 Leverkusen Chinazoline
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE2812635A1 (de) 1978-03-22 1979-09-27 Bayer Ag Heterocyclische verbindungen
JPS55118917A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
JPS55118918A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6017375B2 (ja) 1979-06-20 1985-05-02 三菱電機株式会社 ポリアミド樹脂の製造方法
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JPS6310777A (ja) 1986-07-01 1988-01-18 Hokuriku Seiyaku Co Ltd ピペラジンアセトアミド誘導体
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
CH671155A5 (cg-RX-API-DMAC7.html) 1986-08-18 1989-08-15 Clinical Technologies Ass
US6696250B1 (en) 1986-12-03 2004-02-24 Competitive Technologies, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
EP0525960B1 (en) 1991-06-18 1996-03-20 American Home Products Corporation Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma
EP0636156B1 (en) 1992-04-14 1997-07-30 Cornell Research Foundation, Inc. Dendritic based macromolecules and method of production
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
FI951367A7 (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
JPH10507441A (ja) 1994-08-12 1998-07-21 プロ−ニューロン， インコーポレイテッド オキシプリンヌクレオシドを用いる敗血症または炎症性疾患の処置方法
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5948664A (en) 1996-02-29 1999-09-07 The Regents Of The University Of California PI 3-kinase polypeptides
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
SK284108B6 (sk) 1996-05-15 2004-09-08 Pfizer Inc. 2,3-Disubstituované 4(3H)-chinazolinóny, ich použitie a farmaceutické kompozície s ich obsahom
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
ES2199366T3 (es) 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
ID22711A (id) 1997-02-28 1999-12-09 Pfizer Prod Inc Atropisomer dari 3-aril-4(3h)-kinazolinon dan penggunaannya sebagai antagonis reseptor-ampa
DE69831446T2 (de) 1997-06-09 2006-06-14 Pfizer Prod Inc Chinazolin-4-on AMPA Antagonisten
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
AU8280798A (en) 1997-07-03 1999-01-25 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
JP2002500188A (ja) 1998-01-08 2002-01-08 ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション Ａ２ａアデノシンレセプター作動因子
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
AUPQ136299A0 (en) 1999-07-02 1999-07-22 Microsystem Controls Pty Ltd Coin validation
US6046049A (en) 1999-07-19 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of PI3 kinase p110 delta expression
AU774748B2 (en) 1999-10-27 2004-07-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
CN1891699A (zh) 2000-01-24 2007-01-10 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
AU2972701A (en) 2000-02-07 2001-08-14 Bristol Myers Squibb Co 3-aminopyrazole inhibitors of cyclin dependent kinases
NZ522076A (en) 2000-04-25 2005-08-26 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6518227B2 (en) * 2001-02-13 2003-02-11 Robert Woosley Solvent composition for denture adhesive
US7026330B2 (en) 2002-05-30 2006-04-11 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
PL374718A1 (en) 2002-07-10 2005-10-31 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
GB0217777D0 (en) 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
CA2400254A1 (en) 2002-09-19 2004-03-19 University Health Network Compositions and methods for treating heart disease
US7511041B2 (en) 2002-09-30 2009-03-31 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
CA2508601A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
CA2510851A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
CN1826331A (zh) 2003-04-03 2006-08-30 塞马福尔药业公司 Pi－3激酶抑制剂前药
BRPI0411092A (pt) 2003-06-05 2006-07-18 Warner Lambert Co benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
EP1644364A1 (en) 2003-06-05 2006-04-12 Warner-Lambert Company LLC Tetrazol benzofurancarboxamides with pi3k activity as therapeutic agents
WO2004108713A1 (en) 2003-06-05 2004-12-16 Warner-Lambert Company Llc Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents
ATE365735T1 (de) 2003-06-05 2007-07-15 Warner Lambert Co Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
JP2006526605A (ja) 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 治療剤としての３−置換インドール類及びそれらの誘導体
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
CN102229609A (zh) 2004-05-13 2011-11-02 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
EP1755609A1 (en) 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
EP1750715A1 (en) 2004-06-04 2007-02-14 Icos Corporation Methods for treating mast cell disorders
BRPI0515081B8 (pt) 2004-09-09 2021-05-25 Natco Pharma Ltd composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida
CA2598409A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
WO2009058361A1 (en) 2007-10-31 2009-05-07 Dynavax Technologies Corp. Inhibition of type i ifn production
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US20110294803A1 (en) 2008-12-04 2011-12-01 Law Amanda J Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
EP2379510B1 (en) 2008-12-24 2016-10-26 Prana Biotechnology Ltd Quinazolinone compounds
PE20120602A1 (es) 2009-03-24 2012-05-21 Gilead Calistoga Llc ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
MX2011011036A (es) 2009-04-20 2012-01-20 Gilead Calistoga Llc Metodos de tratamiento para tumores solidos.
WO2011032277A1 (en) 2009-09-18 2011-03-24 Boehringer Ingelheim International Gmbh Quinazolinone derivatives as viral polymerase inhibitors
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
UY34656A (es) 2012-03-05 2013-10-31 Gilead Calistoga Llc Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación
SG11201501173SA (en) 2012-08-08 2015-05-28 Kbp Biosciences Co Ltd PI3Kδ INHIBITOR
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
SG11201604825VA (en) 2013-12-20 2016-07-28 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
MA40059A (fr) 2014-06-13 2015-12-17 Gilead Sciences Inc Inhibiteurs de la phosphatidylinositol 3-kinase

Also Published As

Publication number Publication date
EP1761540A1 (en) 2007-03-14
WO2005113554A3 (en) 2006-04-06
CY2016046I2 (el) 2017-11-14
IL179176A (en) 2015-10-29
US20160075705A1 (en) 2016-03-17
LUC00005I1 (cg-RX-API-DMAC7.html) 2017-02-21
EP2612862A2 (en) 2013-07-10
AU2005245875C1 (en) 2017-08-31
US20130231356A1 (en) 2013-09-05
EP2612862A3 (en) 2014-01-08
US8980901B2 (en) 2015-03-17
AU2005245875B2 (en) 2009-07-30
ME02695B (me) 2017-10-20
WO2005113556A1 (en) 2005-12-01
HRP20161657T1 (hr) 2017-02-10
NL300867I2 (cg-RX-API-DMAC7.html) 2017-05-09
LUC00005I2 (cg-RX-API-DMAC7.html) 2017-05-02
HUE030839T2 (en) 2017-06-28
EP3153514B1 (en) 2021-04-21
US8586597B2 (en) 2013-11-19
IL179176A0 (en) 2007-03-08
EP3153514A1 (en) 2017-04-12
PT3153514T (pt) 2021-06-25
US20130116266A1 (en) 2013-05-09
US7932260B2 (en) 2011-04-26
CN101031569B (zh) 2011-06-22
PT2612862T (pt) 2016-12-15
US8207153B2 (en) 2012-06-26
ES2605792T3 (es) 2017-03-16
US20200017503A1 (en) 2020-01-16
US20080275067A1 (en) 2008-11-06
US20100256168A1 (en) 2010-10-07
EP3943494A1 (en) 2022-01-26
FR17C1007I1 (fr) 2017-04-21
USRE44599E1 (en) 2013-11-12
LTPA2017004I1 (lt) 2017-03-10
WO2005113554A2 (en) 2005-12-01
SI2612862T1 (sl) 2017-04-26
ME02688B (me) 2017-10-20
LT2612862T (lt) 2017-01-25
US20120015964A1 (en) 2012-01-19
CY2016046I1 (el) 2017-11-14
BE2017C002I2 (cg-RX-API-DMAC7.html) 2024-08-08
CY1118493T1 (el) 2017-07-12
IL241732A0 (en) 2015-11-30
US10906907B2 (en) 2021-02-02
US8993583B2 (en) 2015-03-31
JP2007537291A (ja) 2007-12-20
CY1118516T1 (el) 2017-07-12
US9149477B2 (en) 2015-10-06
US8779131B2 (en) 2014-07-15
US20210332047A1 (en) 2021-10-28
CN102229609A (zh) 2011-11-02
IL281945A (en) 2021-05-31
US20140121223A1 (en) 2014-05-01
USRE44638E1 (en) 2013-12-10
LTC1761540I2 (lt) 2019-04-10
LT1761540T (lt) 2017-02-27
PL2612862T3 (pl) 2017-08-31
HUE030950T2 (en) 2017-06-28
CA2566609A1 (en) 2005-12-01
EP1761540B1 (en) 2016-09-28
PL1761540T3 (pl) 2017-06-30
CN101031569A (zh) 2007-09-05
PT1761540T (pt) 2016-12-07
DK1761540T3 (en) 2016-11-21
SI3153514T1 (sl) 2022-02-28
AU2009230739A1 (en) 2009-11-12
US10336756B2 (en) 2019-07-02
RS55546B1 (sr) 2017-05-31
HUS1700006I1 (hu) 2017-03-28
IL241732B (en) 2019-10-31
RS55551B1 (sr) 2017-05-31
US20140121224A1 (en) 2014-05-01
HRP20161751T1 (hr) 2017-04-07
US20100256167A1 (en) 2010-10-07
CA2566609C (en) 2012-06-26
US20140378479A1 (en) 2014-12-25
ES2607804T3 (es) 2017-04-04
IL269976B (en) 2021-04-29
AU2005245875A1 (en) 2005-12-01
DK2612862T3 (en) 2016-12-05
FR17C1007I2 (fr) 2018-03-23
EP2612862B1 (en) 2016-09-14
ES2873875T3 (es) 2021-11-04

Similar Documents

Publication Publication Date Title
LT1761540T (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
PL1622897T3 (pl) Inhibitory 3-kinazy fosfatydyloinozytolu
ZA200802485B (en) Phosphatidylinositol 3-kinase inhibitors and methods of their use
IL205747A0 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
ZA200701942B (en) Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
ZA200704888B (en) Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
ZA200904531B (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
IL197933A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
PL1811998T3 (pl) Triazole użyteczne jako inhibitory kinaz białkowych
ZA200710218B (en) Mitotic kinesin inhibitors and methods of use thereof
IL172426A0 (en) Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
GB0422439D0 (en) Inhibitors of infection
ZA200904534B (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
ZA200700751B (en) Azalndoles useful as inhibitors of protein kinases
HK1147258A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
IL166180A0 (en) Novel drug compositions based on novel anticholinergies and inhibitors of egfr kinase
HK1133006A (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use